A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Phase
II
Summary

Evaluate the effects of an investigational cell and gene treatment called MB-CART2019.1 on the cancer cells in patients who have relapsed (responded to treatment but then returns) and/or refractory (has not responded to initial treatment) DLBCL.

Description
Phase II MB-CART2019.1 for R/R DLBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL